Guide Oligonucleotides for ADAR-Mediated MECP2 Editing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Rett syndrome, a neurodevelopmental disorder caused by MECP2 gene mutations, lack a cure and existing methods for editing the MECP2 gene are inefficient and can disrupt endogenous expression levels.
Innovation Solution
The use of guide oligonucleotides capable of ADAR-mediated adenosine to inosine alteration to specifically edit MECP2 polynucleotides, allowing for the correction of pathogenic mutations without transducing or transfecting cells with genetically engineered enzymes, thereby alleviating symptoms of Rett syndrome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used to deliver editing enzymes to cells, then gene editing efficiency is improved, but immune responses are triggered
Solution Approach 1:
The patent uses guide oligonucleotides as intermediaries to recruit endogenous ADAR enzymes to the target MECP2 gene sequence. This intermediary approach allows precise delivery of editing activity to the specific genomic location without requiring viral vector delivery of engineered enzymes, thereby achieving gene editing efficiency while avoiding immune responses.
2Productivity
If genetically engineered editing enzymes are transduced into cells, then editing capability is enhanced, but cellular disruption occurs
Solution Approach 1:
The patent leverages the cell's own endogenous ADAR enzymes to perform the editing function. By designing guide oligonucleotides that recruit these naturally present enzymes to the target site, the system achieves enhanced editing capability without introducing foreign genetic material that could disrupt cellular integrity.
3Manufacturing precision
If existing gene editing methods are applied to MECP2, then mutation correction is achieved, but endogenous expression levels are disrupted
Solution Approach 1:
The patent applies local quality by using guide oligonucleotides that are highly specific to the mutant MECP2 sequence. This specificity ensures that editing occurs only at the precise location of the pathogenic mutation, correcting the error while leaving the surrounding genomic regions and endogenous expression regulation mechanisms undisturbed.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables site-specific editing of the MECP2 gene, preserving endogenous expression levels and avoiding immune responses associated with viral vectors, effectively treating Rett syndrome by correcting disease-causing mutations.
Implementation Method 1
a guide oligonucleotide capable of effecting an adenosine deaminase acting on RNA (ADAR)-mediated adenosine to inosine alteration in the target gene
Data Source
AI summary
The present invention relates to methods and compositions for editing a MECP2 polynucleotide, e.g., a MECP2 polynucleotide comprising a SNP associated with Rett syndrome. The invention also relates to methods and compositions for treating or preventing Rett syndrome in a subject.